Licari A, De Amici M, Nigrisoli S, Marseglia A, Caimmi S, Artusio L, Marseglia G L
Immuno‑Pneumo‑Allergy Unit Department of Pediatrics, University of Pavia, Fondazione IRCCS San Matteo, Pavia, Italy -
Minerva Pediatr. 2014 Oct;66(5):363-7.
Recurrent respiratory infections (RRI) constitute a social problem for both the pharmaco-economic impact and the burden for the family. Pidotimod is a synthetic immunostimulant. The aim of this study was to evaluate the effects of pidotimod on RRI prevention in children.
Globally, 100 children (49 males, mean age 4.7 ± 1.2 years) with RRI were enrolled in the study. At baseline, children were randomly assigned to the treatment with pidotimod 400 mg/die or not for two months. Children were visited at baseline, after 30 (T1) and 60 (T2) days, and at follow-up (120 days; T3). Number of children with upper and lower airways symptoms, medications use, school attendance, and paediatric visits for RRI were evaluated.
Pidotimod treatment was able of significantly reducing the number of children with upper and lower airways symptoms, and medications use, increasing school attendance, and reducing pediatric visits for RRI.
This study provided the evidence that pidotimod may be able of preventing RRI in children.
反复呼吸道感染（RRI）对药物经济学及家庭负担而言均构成一个社会问题。匹多莫德是一种合成免疫刺激剂。本研究旨在评估匹多莫德对预防儿童反复呼吸道感染的效果。
全球共有100名患有反复呼吸道感染的儿童（49名男性，平均年龄4.7±1.2岁）纳入本研究。在基线时，将儿童随机分为接受400mg/日匹多莫德治疗组或不接受治疗组，为期两个月。在基线时、30天（T1）和60天（T2）后以及随访时（120天；T3）对儿童进行访视。评估有上、下呼吸道症状的儿童数量、药物使用情况、上学出勤率以及因反复呼吸道感染的儿科就诊次数。
匹多莫德治疗能够显著减少有上、下呼吸道症状的儿童数量以及药物使用，提高上学出勤率，并减少因反复呼吸道感染的儿科就诊次数。
本研究提供了证据表明匹多莫德可能能够预防儿童反复呼吸道感染。
